Topics

PSGL-1: A Novel Immune Target for B-Cell Lymphoma

Cancer Immunotherapy Tumor Microenvironment Intercellular Communication & Diseases Chronic Inflammation

P-selectin glycoprotein ligand-1, encoded by SELPLG and also known as CD162, is best established as a leukocyte adhesion molecule that supports rolling and trafficking through interactions with selectins. Work in tumor immunology has added a second identity: PSGL-1 can function as an inhibitory receptor on chronically stimulated T cells. This has made it a candidate immune checkpoint distinct from PD-1 and CTLA-4. The relevance to B-cell lymphoma is supported by recent preclinical evidence showing that antibody blockade of PSGL-1 strengthened T-cell responses against lymphoma. This finding extends a concept developed largely in solid-tumor and chronic-stimulation models into hematologic malignancy. The strategy remains early, however, and should be described as a mechanistically grounded experiment rather than a clinically validated lymphoma treatment[1][2].

PSGL-1 is a heavily glycosylated mucin-like protein whose selectin binding depends on appropriate post-translational modification. In tumors, persistent ligation can reinforce dysfunctional CD4 and CD8 T-cell states, reduce effector activity, and cooperate with other inhibitory pathways in the tumor microenvironment. Blocking the receptor may therefore release T cells from chronic inhibitory signaling while also altering leukocyte localization and cellular contacts. Its proposed interaction with inhibitory ligands under tumor-associated conditions further links adhesion biology to checkpoint control. The direct B-cell lymphoma study reported enhanced T-cell function after PSGL-1 antibody blockade, consistent with a checkpoint mechanism. Broader lymphoma research also shows that constitutive PSGL-1 expression can intersect with CD30 and T-cell receptor pathways in anaplastic large T-cell lymphoma, emphasizing that the protein’s role depends on whether it is expressed by immune effectors, malignant cells, or both[1][2][3].

Therapeutically, PSGL-1 blockade could be explored as monotherapy in immunologically responsive lymphoma or as a partner for anti-PD-1 antibodies, bispecific T-cell engagers, or CAR-T cells. A distinct attraction is the possibility of improving endogenous or transferred T-cell function without targeting a B-cell lineage antigen directly. Yet systemic PSGL-1 intervention may also affect normal leukocyte trafficking, vascular adhesion, and inflammatory recruitment. Expression on multiple hematopoietic populations creates pharmacologic complexity and may increase target-mediated clearance of an antibody. Combination experiments should therefore test both antitumor synergy and changes in normal immune-cell distribution. These properties make dose, format, epitope, and Fc function important design variables, and they caution against assuming that genetic deletion and therapeutic antibody blockade will produce identical biology[1][2].

Before clinical translation, investigators need independent validation in multiple B-cell lymphoma models, human tumor samples, and systems that preserve the native immune microenvironment. Studies should define the dominant ligand, downstream signaling partners, cellular source of therapeutic benefit, and relationship to PD-1, VISTA, and established exhaustion programs. Biomarkers might include PSGL-1 density, selectin or VISTA availability, T-cell differentiation state, and changes in trafficking after treatment. Pharmacokinetic work should determine whether widespread cellular expression prevents sustained receptor occupancy in tumor tissue. Toxicology must examine infection defense, thrombosis-related interactions, inflammatory tissue recruitment, and recovery after repeated dosing. PSGL-1 offers a credible new checkpoint hypothesis for B-cell lymphoma, but its value will depend on showing a reproducible therapeutic window and identifying patients in whom inhibitory signaling outweighs its normal adhesion functions[1][2][3].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • GMP Small Molecules
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-11109 Resatorvid
Resatorvid (TAK-242) is a selective Toll-like receptor 4 (TLR4) inhibitor. Resatorvid inhibits NO, TNF-α and IL-6 production with IC50s of 1.8 nM, 1.9 nM and 1.3 nM, respectively. Resatorvid downregulates expression of TLR4 downstream signaling molecules MyD88 and TRIF. Resatorvid inhibits autophagy and plays pivotal role in various inflammatory diseases.
Toll-like Receptor (TLR)   TNF Receptor   Interleukin Related   Autophagy  
Prostate Cancer   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
536
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L948 PD-1/PD-L1 Lead-like Library
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy. A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity. Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.

Focused and target libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-N0822 Shikonin
Shikonin is a major component of a Chinese herbal medicine named zicao. Shikonin is a potent TMEM16A chloride channel inhibitor with an IC50 of 6.5 μM. Shikonin is a specific pyruvate kinase M2 (PKM2) inhibitor and can also inhibit TNF-α and NF-κB pathway. Shikonin decreases exosome secretion through the inhibition of glycolysis. Shikonin inhibits AIM2 inflammasome activation.
Exosomes   Chloride Channel   Pyruvate Kinase   NF-κB   TNF Receptor   HIV   AIM2  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
74
HY-A0003 Lenalidomide
Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8+ T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury.
Molecular Glues   Ligands for E3 Ligase   IKZF Family   Casein Kinase   Apoptosis   Pyroptosis   MDM-2/p53   TNF Receptor  
Inflammation or Immune System Disease   Renal Disease   Chronic Lymphocytic Leukemia   Diffuse Large B-cell Lymphoma   Multiple Myeloma   Myelodysplastic Syndrome   Liver Failure  
63
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-N0182 Fisetin
Fisetin is a natural flavonol found in many fruits and vegetables with various benefits, such as antioxidant, anticancer, neuroprotection effects.
Sirtuin   PPAR   TNF Receptor  
Digestive System Disease   Prostate Cancer   Viral Infection   Depression   Digestive System Inflammation   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
35
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-P9970 Infliximab
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.

Species: Human

TNF Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Lung Cancer   Breast Cancer  
30
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-P9908 Adalimumab
Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Species: Human

TNF Receptor   Bacterial  
Cancer   Autoimmune Disease  
20
HY-108847 Etanercept
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
TNF Receptor   Bacterial  
Cancer   Rheumatoid Arthritis  
16
HY-15526 PSI-697
PSI-697 is an oral P-selectin inhibitor with an IC50 of 125 μM.
P-selectin  
Cancer  
9
HY-107632 GYY4137
GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity.
Apoptosis   STAT   NF-κB   NO Synthase   COX   TNF Receptor   Interleukin Related  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
8
HY-P99032 Monalizumab
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).

Species: Human

Checkpoint Kinase (Chk)   IFNAR  
Breast Cancer   Non-Small Cell Lung Cancer  
7
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-106139 Bimosiamose
Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects.
P-selectin   L-Selectin   E-Selectin  
Inflammation or Immune System Disease   SARS-CoV-2 Infection  
4
HY-102022 α-Galactosylceramide
α-Galactosylceramide (α-GalCer) is a synthetic glycolipid with antitumorial and immunostimulatory. α-Galactosylceramide is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide plus CD1d binds the NKT cell TCR (T cell antigen receptor).
Transmembrane Glycoprotein   Interleukin Related   CD1  
Inflammation or Immune System Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   Hepatitis Virus Infection  
4
HY-P99042 Polatuzumab
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity.

Species: Human

Transmembrane Glycoprotein   ADC Antibodies  
CNS Neoplasm   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
3
HY-P99126 Anti-Mouse/Human CD44 Antibody (IM7)
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma.

Species: Human/Mouse

Transmembrane Glycoprotein   CD44  
Cancer   Inflammation or Immune System Disease   Arthritis  
3
HY-103358 KF38789
KF38789 is a selective inhibitor of P-selectin-PSGL-1 binding. KF38789 inhibits the binding of U937 cells to immobilized P-selectin immunoglobulin G chimeric protein (P-selectin-Ig) with an IC50 value of 1.97 μM.
P-selectin  
Inflammation or Immune System Disease  
2
HY-P99051 Tinurilimab
Tinurilimab (Bay 1834942) is an anti-CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) humanized IgG2 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. Tinurilimab shows an increased tumor cell killing effect in the tumor-cell/T-cell co-culture system.

Species: Human

Transmembrane Glycoprotein  
Cancer   Inflammation or Immune System Disease  
2
HY-P99711 Loncastuximab
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).

Species: Human

CD19   ADC Antibodies  
Cancer  
2
HY-P9987A Crizanlizumab (anti-P-selectin)
Crizanlizumab (anti-P-selectin) is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.
P-selectin  
Inflammation or Immune System Disease  
1
HY-N0620 Mulberroside C
Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a Kd value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser1756 site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease.
HCV   Enterovirus   PERK   Calcium Channel   P-selectin   HCN Channel   Ras   ERK   DNA/RNA Synthesis  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Hepatitis C Virus Infection   Staphylococcus Aureus Infection  
1
HY-P991447 Anti-VSIR/VISTA Antibody (SG7)
Anti-VSIR/VISTA Antibody (SG7) is an antibody targeting VISTA, with a Kd of 0.14 nM for human VISTA and 1 nM for mouse VISTA. Anti-VSIR/VISTA Antibody (SG7) blocks the function of VISTA, prevents VISTA from binding to T cells, restores suppressed T cell activation, and blocks the interactions between VISTA and PSGL-1 as well as VSIG3. Anti-VSIR/VISTA Antibody (SG7) slows tumor growth, reduces PMN-MDSCs, and increases the numbers of CD4+ and CD8+ T cells in the tumor microenvironment. Anti-VSIR/VISTA Antibody (SG7) can be used in studies related to melanoma, colon cancer, and breast cancer.

Species: Human

VISTA  
Breast Cancer   Colorectal Cancer   Melanoma  
1
HY-120231 Z-VRPR-FMK
Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression.
MALT1   NF-κB   MMP  
Cancer  
1
HY-P99263 Inclacumab
Inclacumab (Anti-Human selectin P Recombinant Antibody) is a human monoclonal IgG4 antibody selectively targets P-selectin with a Kd value of 9.9 nM. Inclacumab inhibits P-selectin glycoprotein ligand 1 (PSGL-1) mimetic peptide bind with P-selectin with an IC50 value of 1.9 μg/mL and strongly inhibits cell adhesion.

Species: Human

P-selectin  
Blood or Cardio-cerebrovascular Disease  
1
HY-P99040 Onvatilimab
Onvatilimab (JNJ-61610588) is a human IgG1κ anti-VISTA (V-domain Ig Suppressor of T-cell Activation) monoclonal antibody. Onvatilimab can be used in colorectal cancer research.

Species: Human

VISTA  
Cancer  
1
HY-P9987 Crizanlizumab
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease.

Species: Human

P-selectin  
Blood or Cardio-cerebrovascular Disease  
1
HY-P99117 Cadonilimab
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Species: Human

PD-1/PD-L1   CTLA-4  
Inflammation or Immune System Disease   Gastric Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-132253 Polatuzumab vedotin
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The antibody portion is Polatuzumab (HY-P99042), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
Antibody-Drug Conjugates (ADCs)   Transmembrane Glycoprotein  
Leukemia/Lymphoma/Myeloma  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-Y1089 4-Dimethylaminopyridine
4-Dimethylaminopyridine is an acyl transfer catalyst. 4-Dimethylaminopyridine is used for labeling and analysis of glycoproteins on the surface of living cells. 4-Dimethylaminopyridine reduces dyskinesia attacks.
Biochemical Assay Reagents   Transmembrane Glycoprotein  
Neurological, Eye or Ear Disease  
1
HY-P990007 Tulisokibart
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.

Species: Human

TNF Receptor  
Digestive System Inflammation   Crohn's Disease   Ulcerative Colitis  
1
HY-P70803 P-selectin Protein, Human (HEK293, His)
P-selectin is a Ca(2+)-dependent receptor on myeloid cells that critically binds to sialic acid-Lewis X on neutrophils and monocytes, promoting the interaction between activated endothelial cells or platelets and leukocytes interaction. This binding primarily to SELPLG/PSGL1 and PODXL2 is critical for rapid rolling of leukocytes during early inflammation. P-selectin Protein, Human (HEK293, His) is the recombinant human-derived P-selectin protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

1
HY-P7537 BCL2 Protein, Human (His)
BCL2 Protein regulates the mitochondrial membrane permeability, and inhibits the caspase activity, thereby suppressing the apoptosis in various cell types. BCL2 Protein interacts with BECN1 and AMBRA1, and inhibits the autophagy. BCL2 Protein, Human (His) is the human-derived resombinant BCL2 Protein that is expressed in in E. coli with a His tag at the C-terminus.

Species: Human; Source: E. coli

1
HY-P72101 BCL2 Protein, Mouse (His)
BCL2 protein crucially regulates cell death by controlling mitochondrial membrane permeability. It interacts with caspases in a feedback loop, inhibiting their activity. BCL2 prevents cytochrome c release from mitochondria and binds to apoptosis-activating factor (APAF-1). BCL2 Protein, Mouse (His) is the recombinant mouse-derived BCL2 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Mouse; Source: E. coli

1
HY-P702682 CDK4-CCND1 Protein, Human (Active, sf9, GST, Flag, His)
CDK4 protein, acting as a Ser/Thr kinase in the cyclin D-CDK4 complex, critically regulates the G(1)/S transition by phosphorylating and inhibiting RB family members. This activity, specifically hypophosphorylation of RB1 during early G(1) phase, releases E2F and promotes transcription of genes that drive G(1) progression. CDK4-CCND1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK4-CCND1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 4 (CDK4)

1
HY-P702687 CDK6-CCND1 Heterodimer Protein, Human (Active, sf9, GST, Flag, His)
The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK6-CCND1 Heterodimer, expressed by Sf9 insect cells, with N-Flag, N-His, N-GST labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 6 (CDK6)

1
HY-100866 F1324
F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
Bcl-2 Family  
Cancer  
/
HY-172396 PD-L1/VISTA-IN-2
PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects.
PD-1/PD-L1   VISTA  
/
HY-100866A F1324 TFA
F1324 TFA is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC50 of 1 nM. F1324 TFA exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
Bcl-2 Family  
Cancer  
/
HY-P99851 Detumomab
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).

Species: Human

Others  
Cancer  
/
HY-100866B F1324 acetate
F1324 acetate is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6), with an IC50 of 1 nM. F1324 acetate exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
Bcl-2 Family  
Cancer  
/
HY-P992320 BAT-6004
BAT-6004 is a monoclonal antibody that targets CD47 and is a CD47 inhibitor. BAT-6004 can be used in research on acute myeloid leukemia and diffuse large B-cell lymphoma.

Species: Human

CD47  
Acute Myeloid Leukemia   Diffuse Large B-cell Lymphoma  
/
HY-P5472 Tumour-associated MUC1 epitope
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)
Transmembrane Glycoprotein  
/
HY-P11798 P-Selectin binding peptide
P‑Selectin binding peptide is a short peptide that specifically targets P‑selectin. P‑Selectin binding peptide binds with high affinity to P‑selectin, which is highly expressed on activated platelets, inflamed endothelium, and in the tumor microenvironment. P‑Selectin binding peptide is used for precise targeted delivery and intervention in inflammation, thrombosis, and tumors.
P-selectin  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-106428 Icrocaptide
Icrocaptide (ITF1697) is a stable Lys-Pro-containing peptide that inhibits the intracellular Ca2+-dependent fusion of Weibel-Palade bodies with the plasma membrane. Icrocaptide exerts its activity at the early stages of endothelial activation and inhibits P-selectin and von Willebrand factor secretion. Icrocaptide can be used for the study of a variety of microvascular disorders.
P-selectin  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P992417 MT-3724
MT-3724 is a CD20-targeted endotoxin B. MT-3724 binds to CD20, triggers receptor internalization, traffics to the endoplasmic reticulum, and induces permanent ribosomal inactivation to mediate cell killing. MT-3724 can inhibit protein synthesis and promote tumor cell apoptosis. MT-3724 can be used for the research of relapsed or refractory B-cell non-Hodgkin’s lymphomas and diffuse large B-cell lymphoma.

Species: Human

CD20   Apoptosis  
Diffuse Large B-cell Lymphoma  
/
HY-170793 PD-L1/VISTA-IN-1
PD-L1/VISTA-IN-1 (Compound P17) is an orally active dual-target inhibitor of PD-L1 and VISTA. PD-L1/VISTA-IN-1 can block the PD-1/PD-L1 interaction (IC50: 0.1492 μM) and the VISTA pathway (KD: 0.2723 μM), thereby reactivating T cells. PD-L1/VISTA-IN-1 has anti-tumor activity.
PD-1/PD-L1   VISTA  
Cancer  
/
HY-P4544 Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression.
MALT1   NF-κB   MMP  
Cancer  
/
HY-P99501 Zuberitamab
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma.

Species: Human

CD20  
Cancer  
/
HY-P991765 Anti-VISTA Antibody (GG8)
Anti-VISTA Antibody (GG8) reacts with human VISTA. Endogenous VISTA has inhibitory effects both as a ligand on APCs and as a receptor on T cells. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species: Human

VISTA  
Cancer   Inflammation or Immune System Disease  
/
HY-P991432 VTX-0811
VTX-0811 is a human IgG4 monoclonal antibody (mAb) targeting PSGL1/CD162. VTX-0811 up-regulates TNF-α/NF-κB and chemokine-mediated signaling and down-regulates oxidative phosphorylation, fatty acid metabolism, and Myc signaling pathways. VTX-0811 increases the proportion of CD8+ T cells among infiltrating T cells. VTX-0811 has antitumor activity in a humanized mouse PDX model of melanoma.

Species: Human

TNF Receptor   NF-κB   c-Myc  
Cancer  
/
HY-P991369 EBU-141
EBU-141 is a human monoclonal antibody (mAb) targeting CD75/ST6GAL1. EBU-141 can be used in B-cell lymphoma and multiple myeloma research.

Species: Human

Sialyltransferase  
Cancer  
/
HY-P991345 MEDI-0680
MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-P11698 Guanidino-G-Clamp-PNA
Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis.
DNA Alkylator/Crosslinker   Transthyretin (TTR)  
Diffuse Large B-cell Lymphoma  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-P10715 Fmoc-KCRGDK
Fmoc-KCRGDK is a self-assembling peptide that can be used to prepare hydrogels and assist in drug delivery for immune checkpoint inhibitors. Fmoc-KCRGDK can be applied in cancer immunotherapy research.
Others  
Inflammation or Immune System Disease  
/
HY-P991839 Anti-CD19 Antibody (FMC63)
Anti-CD19 Antibody (FMC63) is an antibody that binds to CD19, with a human Kd value ranging from 0.42 nM to 149 nM. Anti-CD19 Antibody (FMC63) mediates tumor cell killing, cytokine secretion, stable CAR expression, T cell activation and memory differentiation. Anti-CD19 Antibody (FMC63) fails to eliminate lymphoma cells carrying CD19 point mutations or co-expressing FMC63-CAR19, induces higher levels of activation-induced cell death, and reduces cell persistence. Anti-CD19 Antibody (FMC63) can be used in research related to B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma, etc.

Species: Human

CD19  
Acute Lymphoblastic Leukemia   Non-Hodgkin Lymphoma   Diffuse Large B-cell Lymphoma  
/
HY-141432G NX-1607 (GMP)
NX-1607 (Cbl-b-IN-3) (GMP) is a GMP-grade NX-1607 (HY-141432). GMP-grade small molecules can be used as adjuvant agents in cell therapy. NX-1607 (GMP) enhances antigen recall, reduces T cell exhaustion and increases cytokine production. NX-1607 is an inhibitor of Cbl-b (an E3 enzyme).
E1/E2/E3 Enzyme  
Cancer   Inflammation or Immune System Disease  
/
HY-W703549 Aderbasib-d3
Aderbasib-d3 (INCB007839-d3) is deuterium labeled Aderbasib. Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2+?breast cancer, gliomas, et al.
Isotope-Labeled Compounds   MMP  
/
HY-179630 MS102
MS102 is an orally active ubiquitin specific peptidase 2 (USP2) inhibitor with an IC50 of 5.46 μM. MS102 has viable antiviral activity against ACE2-dependent coronaviruses. MS102 significantly reduces V-domain Ig suppressor of T cell activation (VISTA) protein abundance in vitro and in vivo. MS102 can be used for the study of SARS-CoV-2. MS102 can be used in combination with anti-PD-1 immunotherapy to enhance the anti-tumor immune response.
Deubiquitinase   SARS-CoV   VISTA  
Cancer   SARS-CoV-2 Infection  
/
HY-153939S Idasanutlin-d3-1
Idasanutlin-d3-1 (RG7388-d3-1) is the deuterated-labeled Idasanutlin (HY-15676). Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
Isotope-Labeled Compounds   MDM-2/p53   E1/E2/E3 Enzyme   Apoptosis   Pyroptosis   Reactive Oxygen Species (ROS)   Caspase  
Musculoskeletal and Skin Disease   Colorectal Cancer   Melanoma   Neuroblastoma   Osteosarcoma   Non-Small Cell Lung Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma  
/
HY-P991776 Anti-Mouse VISTA Antibody (8G8)
Anti-Mouse VISTA Antibody (8G8) reacts with mouse VISTA. Anti-Mouse VISTA Antibody (8G8) is an agonistic antibody with immunosuppressive properties. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305).

Species: Mouse

VISTA  
Immunosuppression  
/
HY-Q25865 MG-V-53
MG-V-53 is a potent small molecule V domain T-cell activating immunoglobulin suppressor (VISTA) inhibitor with IC50 value of 121 nM. MG-V-53 has antitumor activity.
VISTA  
Cancer  
/
HY-P990732 Cepeprubart
Cepeprubart is an anti-SELPLG human IgG2 κ monoclonal antibody. Recommend Isotype Controls: Human IgG2 kappa, Isotype Control (HY-P99002).

Species: Human

Others  
Inflammation or Immune System Disease  
/
HY-P11280A PRAME peptide (425-433) acetate
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.
Melanocortin Receptor  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Lung Squamous Cell Carcinoma   Squamous Cell Carcinoma  
/
HY-P1407 Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA
Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA is an irreversible MALT1 protein inhibitor. Z-Val-Arg-Pro-DL-Arg-Fluoromethylketone TFA inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression.
MALT1   NF-κB   MMP  
Cancer  
/
HY-D2188 IMP-2373
IMP-2373 is a low-toxicity activity-based probe targeting covalent pan-deubiquitinase (DUB), which modulates and monitors DUB activity via covalent binding to the catalytic cysteine and active site of DUB. IMP-2373 enables real-time tracking of dynamic intracellular DUB activity in physiologically relevant living cell systems, and quantitative analysis of activity changes induced by pharmacological inhibition or MYC dysregulation. IMP-2373 can be used for research on related diseases such as B-cell lymphoma.
Deubiquitinase  
Leukemia/Lymphoma/Myeloma  
/
HY-P99027 Ieramilimab
Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors.

Species: Human

LAG-3  
Triple-Negative Breast Cancer  
/
HY-N6579 Arvenin I
Arvenin I is a natural cucurbitacin glucoside that activates T cells within the cancer-competitive environment. Arvenin I covalently reacts with and hyperactivates MKK3, thereby reviving the mitochondrial fitness of exhausted T cells through the activation of the p38MAPK pathway. Arvenin I exhibits broad-spectrum antiproliferative against cancer cells. Arvenin I enhances antitumor effects both as a monotherapy and in combination with immune checkpoint inhibitors in mice. Arvenin I can be used for cancer research, such as colon cancer, breast cancer, lung cancer, and ovarian cancer.
p38 MAPK   Mitochondrial Metabolism  
Cancer  
/
HY-P990704 Rilvegostomig
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer.

Species: Human

PD-1/PD-L1   Transmembrane Glycoprotein  
Non-Small Cell Lung Cancer   Endometrial Cancer  
/
HY-169853 M351-0056
M351-0056 is an orally active VISTA agonist with a Kd value of 12.60 μM. M351-0056 inhibits the activation of the JAK2-STAT2 pathway, reduces the phosphorylation levels of JAK2 and STAT2, and regulates type I interferon (IFN-I) and non-canonical NF-κB pathways. M351-0056 decreases the levels of cytokines (IFN-γ, IL-17A, TNF-α, IL-2 and IL-1β). M351-0056 improves imiquimod (HY-B0180)-induced psoriasis-like skin inflammation, reduces autoantibody levels, kidney damage and immune cell expansion in mice susceptible to chronic graft-versus-host disease and lupus, and delays the progression of systemic lupus erythematosus. M351-0056 can be used in research related to psoriasis-like dermatitis and systemic lupus erythematosus.
VISTA   JAK   STAT   IFNAR   NF-κB   Interleukin Related   TNF Receptor  
Systemic Lupus Erythematosus   Psoriasis  
/
HY-N3062 Pinobanksin
Pinobanksin is an antioxidant and anti-ferroptosis agent found in sunflower honey and propolis, with oral activity. Pinobanksin enhances Nrf2-mediated antioxidant defense, inhibits NF-κB inflammation, and suppresses apoptosis and ferroptosis in in vivo models and normal cells. Pinobanksin exhibits apoptosis-inducing effects on B-cell lymphoma cells. Pinobanksin can be used in research related to perfluorooctane sulfonate-induced renal/cardiac toxicity, acute colitis, and B-cell lymphoma.
Apoptosis   Ferroptosis   NF-κB   Keap1-Nrf2  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Colitis  
/
HY-P10887 Pegevongitide
Pegevongitide (AV-001) is a Tie2 agonist. Pegevongitide resists the increased endothelial cell permeability induced by SARS-CoV-2 infection. Pegevongitide activates the angiogenin (angiogenin)/Tie2 signaling pathway. Pegevongitide reduces perivascular space dilation and upregulates perivascular Aquaporin-4 expression. Pegevongitide decreases the expression of TNF-α, PAI-1, CXCL9 and P-selectin, improves white matter integrity, enhances cognitive function and exerts neuroprotective effects. Pegevongitide improves white matter integrity in middle-aged rats with vascular dementia induced by multiple microinfarctions. Pegevongitide can be used in related research on diseases such as COVID-19 and vascular dementia.
Tie   ANGPTL   SARS-CoV   Aquaporin   TNF Receptor   PAI-1   CXCR   P-selectin  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   SARS-CoV-2 Infection  
/
HY-P990120 Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5)
Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) is an anti-rat Kappa Immunoglobulin Light Chain IgG2a monoclonal antibody. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance B cell depletion. Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can enhance T cell exhaustion after the injection of CD4 mAb (HY-P990792) and CD8 mAb (HY-P99129). Anti-Rat Kappa Immunoglobulin Light Chain Antibody (MAR 18.5) can be used for research on immunology.

Species: Rat

Others  
Inflammation or Immune System Disease  
/
HY-P99514 Zalifrelimab
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling.

Species: Human

CTLA-4  
Cancer  
/
HY-P99617 Fianlimab
Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity.

Species: Human

LAG-3  
Inflammation or Immune System Disease   Breast Cancer   Non-Small Cell Lung Cancer  
/
HY-P6442 Chemerin15
Chemerin15 is an anti-inflammatory peptide derived from Chemerin. Chemerin15 binds to ChemR23. Chemerin15 inhibits TNFα-induced activation of Syk, ERK and Src kinases. Chemerin15 increases the expression of p-p38 mRNA and protein. Chemerin15 mediates phagocytosis, resolution of inflammation, CD62L shedding and downregulation of PSGL-1 expression in macrophages and microglia. Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury via ChemR23. Chemerin15 enhances microglial phagocytosis, thereby alleviating cerebral ischemia-reperfusion injury.
Chemerin Receptor   Syk   ERK   Src   p38 MAPK   P-selectin  
Cerebrovascular Disease   Cardiovascular Disease   Ischemia-Reperfusion Injury  
/
HY-P99443 Aselizumab
Aselizumab (HuDreg-55) is an humanized IgG4 mAb against L-selectin. However, L-selectin (CD62L) is a cell adhesion molecule expressed on circulating neutrophils. It regulates migrating cells to chemotaxis towards the site of injury. Aselizumab may be account for a high rate of infections and leucopenia after truma.

Species: Human

P-selectin  
Inflammation or Immune System Disease  
/
HY-P990166 Anti-Mouse PSGL-1/CD162 Antibody (4RA10)
Anti-Mouse PSGL-1/CD162 Antibody (4RA10) is a rat-derived IgG1 κ type antibody inhibitor, targeting to mouse PSGL-1/CD162. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) blocks PSGL signaling and inhibits leukocyte rolling. Anti-Mouse PSGL-1/CD162 Antibody (4RA10) can be used for the researches of inflammation, immunology and infection, such as pneumonia and lymphocytic choriomeningitis virus infection.

Species: Mouse

Apoptosis   Transmembrane Glycoprotein   Arenavirus  
Infection   Inflammation or Immune System Disease  
/
HY-P99483 Blontuvetmab
Blontuvetmab (AT 004) is a canine-derived CD20 monoclonal antibody, and it is used for research on canine B-cell lymphoma.

Species: Canlupfam

CD20  
Cancer  
/
HY-N0600 Ginsenoside F3
Ginsenoside F3 is a saponin extracted from the leaves of Panax ginseng with immunoenhancing and antitumor immunostimulatory activities. Ginsenoside F3 upregulates RIPOR2 with a Kd value of 3.77 μM. Ginsenoside F3 enhances NF‑κB activation, upregulates T‑bet and downregulates GATA‑3, increases the production of IL‑2 and IFN‑γ, decreases the production of IL‑4 and IL‑10, reverses CD8⁺ T‑cell exhaustion, restores cytokine secretion, and enhances antitumor immunity in a mouse non‑small cell lung cancer model. Ginsenoside F3 can be used for the research of non-small cell lung cancer.
Interleukin Related   IFNAR   NF-κB  
Digestive System Disease   Cancer Immunology   Digestive System Inflammation  
/
HY-P99613 Favezelimab
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3. Favezelimab blocks the interaction between LAG-3 and its ligand, MHC class II molecules. Favezelimab is applicable to research on relapsed/refractory classical Hodgkin lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and relapsed/refractory indolent B-cell lymphoma. For the isotype control of Favezelimab, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

LAG-3  
Leukemia/Lymphoma/Myeloma  
/
HY-P991449 LY3415244
LY3415244 is a bispecific antibody that targets and inhibits TIM-3 and PD-L1. LY3415244 blocks the interaction between TIM-3 on immune cells and PD-L1 on the surface of tumor cells, establishes intercellular connections between TIM-3-positive immune cells and PD-L1-positive tumor cells, and blocks dual immunosuppressive signals. LY3415244 alleviates T cell exhaustion and restores T cell proliferation. LY3415244 induces broad-spectrum anti-drug antibodies, which impairs the binding capacity to soluble TIM-3 targets. LY3415244 can be used in research related to various advanced solid tumors.

Species: Human

PD-1/PD-L1   Tim3  
Cancer  
/
HY-132828 Odatroltide
Odatroltide (LT3001; DHDMIQK(KAP)) is a P-selectin inhibitor. Odatroltide is a peptide molecule comprising a tripeptide Pro-Ala-Lys (PAK) and an (S)-6,7-dihydroxy-1,1-dimethyl-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid domain. Odatroltide can restore cerebral blood flow, scavenge free radicals, and inhibit leukocyte migration. Odatroltide possesses thrombolytic and anti-thrombotic activities.
P-selectin  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P990145 Anti-Mouse VISTA Antibody (13F3)
Anti-Mouse VISTA Antibody (13F3) is an anti-mouse VISTA IgG monoclonal antibody. Anti-Mouse VISTA Antibody (13F3) can reverse the immunosuppressive effect of VISTA by blocking its binding to ligands such as VSIG3. Anti-Mouse VISTA Antibody (13F3) exacerbates pulmonary fibrosis (PF) by promoting Th17 cell differentiation. Anti-Mouse VISTA Antibody (13F3) can be used for research on cancer such as breast cancer and PF.

Species: Mouse

VISTA  
Inflammation or Immune System Disease   Breast Cancer  
/
HY-P99166 Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.

Species: Human

PD-1/PD-L1   CTLA-4  
Cancer   Inflammation or Immune System Disease  
/
HY-P99950 Evorpacept
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
CD47  
Leukemia/Lymphoma/Myeloma   Luminal Breast Cancer  
/
HY-P99378 Neihulizumab
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research.

Species: Human

Apoptosis  
Inflammation or Immune System Disease  
/
HY-P99139 Anti-Mouse IL-1b Antibody (B122)
Anti-Mouse IL-1b Antibody (B122) is an anti-mouse IL-1b IgG monoclonal antibody. Anti-Mouse IL-1b Antibody (B122) enhances ferroptosis and increases levels of reactive oxygen species (ROS) combined with Sulfasalazine (SAS) (HY-14655). Anti-Mouse IL-1b Antibody (B122) can reduce monocyte infiltration and alleviate T cell exhaustion by blocking IL-1β signaling. Anti-Mouse IL-1b Antibody (B122) can be used for researches on cancer and cardiovascular conditions such as oral squamous cell carcinoma (OSCC), glioblastoma (GBM) and heart failure.

Species: Mouse

Interleukin Related   Reactive Oxygen Species (ROS)   Ferroptosis  
Blood or Cardio-cerebrovascular Disease   Glioma  
/
HY-P9986 Tiragolumab
Tiragolumab is an immune checkpoint inhibitor binding to the T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab in combination with Atezolizumab (HY-P9904) and Bevacizumab (HY-P9906) has benefit in unresectable hepatocellular carcinoma. Tiragolumab can be used to study non-small cell lung cancer (NSCLC) and melanoma.

Species: Human

CD28  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
/
HY-P9965 Elotuzumab
Elotuzumab (HuLuc 63) is an IgG1 monoclonal antibody targeting the SLAMF7 receptor. Elotuzumab exerts antitumor activity by activating natural killer cells and inducing antibody-dependent cell-mediated cytotoxicity. Elotuzumab can be combined with Lenalidomide (HY-A0003), Dexamethasone (HY-14648), etc., for the research of tumors such as multiple myeloma.

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-P990792 Anti-Mouse CD4 Antibody (GK1.5)
Anti-Mouse CD4 Antibody (GK1.5) is an anti-mouse CD4 IgG2b monoclonal antibody. Anti-Mouse CD4 Antibody (GK1.5) can significantly deplete CD4+ T cells. Anti-Mouse CD4 Antibody (GK1.5) can extend the survival rate of xenograft models. Anti-Mouse CD4 Antibody (GK1.5) can be used for research on immunology. The recommend isotype control of Anti-Mouse CD4 Antibody (GK1.5): Rat IgG2b kappa, Isotype Control (HY-P990682).

Species: Mouse

Transmembrane Glycoprotein  
Inflammation or Immune System Disease   Melanoma  
/
HY-P99054 Tusamitamab
Tusamitamab is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize ADC Tusamitamab ravtansine (SAR408701) (HY-P99542).

Species: Human

Transmembrane Glycoprotein   ADC Antibodies  
Gastric Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
/
HY-P99971 Gemtuzumab
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen. Gemtuzumab affects cell necrosis by specifically targeting CD33 expressed on the surface of leukaemic cell blasts in acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

Species: Human

ADC Antibodies   Transmembrane Glycoprotein  
Cancer  
/
HY-P990673 Vandortuzumab
Vandortuzumab (DSTP-3086S Antibody; RG-7450 Antibody) is a humanized anti-STEAP1 IgG1 antibody and antimitotic agent that can be conjugated with MMAE (HY-15162) to form the antibody-drug conjugate (ADC) Vandortuzumab vedotin. Vandortuzumab vedotin specifically binds to STEAP1 and drives internalization of the complex, releasing the MMAE (HY-15162) payload intracellularly. After binding to tubulin, MMAE inhibits cell division and induces cell death. Vandortuzumab exhibits antitumor activity in preclinical xenograft models of prostate cancer and can be used for research related to metastatic castration-resistant prostate cancer (mCRPC).

Species: Human

ADC Antibodies   Transmembrane Glycoprotein   Mitosis  
Castration-Resistant Prostate Cancer  
/
HY-P73383 P-Selectin Protein, Mouse (HEK293, Fc)
P-selectin is a Ca(2+)-dependent receptor on myeloid cells that specifically binds to carbohydrates on neutrophils and monocytes.It mediates interactions between activated endothelial cells or platelets and leukocytes by recognizing sialic acid-Lewis X.P-Selectin Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived P-Selectin protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P72119 CCND1 Protein, Human (His)
The CCND1 protein is a regulatory component of the cyclin D1-CDK4 complex that coordinates phosphorylation and RB family inhibition to regulate the G(1)/S transition. This promotes the dissociation of E2F from the RB/E2F complex and promotes the transcription of E2F target genes critical for G(1) phase progression. CCND1 Protein, Human (His) is the recombinant human-derived CCND1 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P73690 P-Selectin Protein, Human (HEK293, Fc)
P-selectin is a Ca(2+)-dependent receptor on myeloid cells that critically binds to sialic acid-Lewis X on neutrophils and monocytes, promoting the interaction between activated endothelial cells or platelets and leukocytes interaction. This binding primarily to SELPLG/PSGL1 and PODXL2 is critical for rapid rolling of leukocytes during early inflammation. P-Selectin Protein, Human (HEK293, Fc) is the recombinant human-derived P-Selectin protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P77163 CD162/PSGL-1 Protein, Human (HEK293, His)
CD162/PSGL-1 Protein, a cell surface receptor, plays a crucial role in leukocyte trafficking and adhesion. Dysregulation of CD162/PSGL-1 Protein has been associated with inflammatory diseases and impaired immune responses. Targeting CD162/PSGL-1 Protein may offer potential therapeutic interventions in these conditions by modulating leukocyte trafficking, enhancing immune responses, and managing inflammatory disorders. CD162/PSGL-1 Protein, Human (HEK293, His) is the recombinant human-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P72102 BCL6 Protein, Human (GST)
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human (GST) is the recombinant human-derived BCL6 protein, expressed by E. coli , with N-GST labeled tag.

Species: Human; Source: E. coli

/
HY-P78201 P-Selectin Protein, Human (Biotinylated, HEK293, His-Avi)
P-selectin is a Ca(2+)-dependent receptor on myeloid cells that critically binds to sialic acid-Lewis X on neutrophils and monocytes, promoting the interaction between activated endothelial cells or platelets and leukocytes interaction. This binding primarily to SELPLG/PSGL1 and PODXL2 is critical for rapid rolling of leukocytes during early inflammation. P-Selectin Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived P-Selectin protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P78349 P-Selectin Protein, Mouse (HEK293, His)
P-selectin is a Ca(2+)-dependent receptor on myeloid cells that specifically binds to carbohydrates on neutrophils and monocytes.It mediates interactions between activated endothelial cells or platelets and leukocytes by recognizing sialic acid-Lewis X.P-Selectin Protein, Mouse (HEK293, His) is the recombinant mouse-derived P-Selectin protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P700815 CD162/PSGL-1 Protein, Cynomolgus (HEK293, His)
As a member of the selectin family, CD162/PSGL-1 is mainly expressed in some immune or inflammatory cells. CD162/PSGL-1 deficiency affects myeloid differentiation and lymphocyte maturation and therefore has important implications for cell differentiation. CD162/PSGL-1 can be used as an immune checkpoint modulator and may be a new target for cancer therapy. CD162/PSGL-1 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Cynomolgus; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P72485 CD162/PSGL-1 Protein, Human (HEK293, hFc)
CD162/PSGL-1 Protein, a cell surface receptor, plays a crucial role in leukocyte trafficking and adhesion. Dysregulation of CD162/PSGL-1 Protein has been associated with inflammatory diseases and impaired immune responses. Targeting CD162/PSGL-1 Protein may offer potential therapeutic interventions in these conditions by modulating leukocyte trafficking, enhancing immune responses, and managing inflammatory disorders. CD162/PSGL-1 Protein, Human (HEK293, hFc) is the recombinant human-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P73689 P-Selectin Protein, Rat (HEK293, His)
P-Selectin, a Ca(2+)-dependent receptor on myeloid cells, binds to neutrophils and monocytes via carbohydrates. It interacts with SELPLG to enable rapid leukocyte rolling over vascular surfaces in early inflammation. P-Selectin also interacts with SNX17 and promotes neutrophil adhesion and rolling, requiring SELPLG's sialyl-Lewis X and tyrosine sulfation. P-Selectin Protein, Rat (HEK293, His) is the recombinant rat-derived P-Selectin protein, expressed by HEK293 , with C-His labeled tag.

Species: Rat; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P7800 CD162/PSGL-1 Protein, Mouse (HEK293, Fc)
CD162/PSGL-1 Protein, Mouse (HEK293, Fc) is a recombinant mouse CD162 expressed in HEK 293 cells with a C-Fc tag at the C-terminus. CD162/PSGL-1 Protein plays an important role in immunity and homeostasis .

Species: Mouse; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P702575 BCL6 Protein, Human
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

/
HY-P73687 P-Selectin Protein, Rhesus Macaque (HEK293, His)
P-Selectin Protein, Rhesus Macaque (HEK293, His) is a member of the selectin family of cell adhesion molecules. P-selectin (CD62P) has an N-terminal lectin domain, an epidermal growth factor motif, (generally) nine regulatory protein repeats, a transmembrane section and a short intracytoplasmic tail. P-selectin mediates leukocyte rolling on stimulated endothelial cells and heterotypic aggregation of activated platelets onto leukocytes. P-selectin mediates heterotypic aggregation of activated platelets to cancer cells and adhesion of cancer cells to stimulated endothelial cells. P-selectin glycoprotein ligand-1 (PSGL-1) is a major ligand for P-selectin. P-Selectin Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived P-Selectin protein, expressed by HEK293 , with C-His labeled tag.

Species: Rhesus Macaque; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P702676 CDK2-CCND1 Protein, Human (Active, sf9, GST, Flag, His)
CDK2 is an important serine/threonine protein kinase that plays a critical regulatory role in the cell cycle, especially during meiosis. It phosphorylates various substrates (CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2) and coordinates centrosome duplication and initiation of DNA synthesis at the G1-S transition. CDK2-CCND1 Protein, Human (sf9, GST, Flag, His) is the recombinant human-derived CDK2-CCND1, expressed by Sf9 insect cells, with N-His, N-GST, N-Flag labeled tag.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 2 (CDK2)

/
HY-P77165 CD162/PSGL-1 Protein, Mouse (HEK293)
The CD162/PSGL-1 protein is an SLe(x)-type proteoglycan that mediates rapid rolling of leukocytes through high-affinity interactions with E- and P-selectin, thereby promoting early inflammatory stages.CD162 forms homodimers linked by disulfide bonds and interacts with selectins through the lectin/EGF domain.CD162/PSGL-1 Protein, Mouse (HEK293) is the recombinant mouse-derived CD162/PSGL-1 protein, expressed by HEK293 , with tag free.

Species: Mouse; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P73385 P-Selectin Protein, Rat (HEK293, Fc)
P-Selectin, a Ca(2+)-dependent receptor on myeloid cells, binds to neutrophils and monocytes via carbohydrates. It interacts with SELPLG to enable rapid leukocyte rolling over vascular surfaces in early inflammation. P-Selectin also interacts with SNX17 and promotes neutrophil adhesion and rolling, requiring SELPLG's sialyl-Lewis X and tyrosine sulfation. P-Selectin Protein, Rat (HEK293, Fc) is the recombinant rat-derived P-Selectin protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rat; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P72408 P-selectin Protein, Mouse (Biotinylated, HEK293, Avi-His)
P-selectin is a Ca(2+)-dependent receptor on myeloid cells that specifically binds to carbohydrates on neutrophils and monocytes.It mediates interactions between activated endothelial cells or platelets and leukocytes by recognizing sialic acid-Lewis X.P-selectin Protein, Mouse (Biotinylated, HEK293, Avi-His) is the recombinant mouse-derived P-selectin protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Receptor Proteins Biotinylated Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P73688 P-Selectin Protein, Rhesus Macaque (HEK293, Fc)
P-Selectin Protein, Rhesus Macaque (HEK293, His) is a member of the selectin family of cell adhesion molecules. P-selectin (CD62P) has an N-terminal lectin domain, an epidermal growth factor motif, (generally) nine regulatory protein repeats, a transmembrane section and a short intracytoplasmic tail. P-selectin mediates leukocyte rolling on stimulated endothelial cells and heterotypic aggregation of activated platelets onto leukocytes. P-selectin mediates heterotypic aggregation of activated platelets to cancer cells and adhesion of cancer cells to stimulated endothelial cells. P-selectin glycoprotein ligand-1 (PSGL-1) is a major ligand for P-selectin. P-Selectin Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived P-Selectin protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Rhesus Macaque; Source: HEK293

CD Antigens Receptor Proteins Platelet CD Proteins Endothelial cell CD Proteins Cell Adhesion Molecules (CAMs) P-Selectin/CD62P Selectin

/
HY-P77162 CD162/PSGL-1 Protein, Human (HEK293, His-Fc)
CD162/PSGL-1 Protein is a sialomucin expressed on leukocytes, which through high affinity, calcium-dependent interactions with E- and P-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. CD162/PSGL-1 Protein, Human (HEK293, His-Fc) is the recombinant human-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-His, C-hFc labeled tag.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P77164 CD162/PSGL-1 Protein, Human (HEK293, mFc)
CD162/PSGL-1 Protein is a sialomucin expressed on leukocytes, which through high affinity, calcium-dependent interactions with E- and P-selectins, mediates rapid rolling of leukocytes over vascular surfaces during the initial steps in inflammation. CD162/PSGL-1 Protein, Human (HEK293, mFc) is the recombinant human-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-mFc labeled tag.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P78819 CD162/PSGL-1 Protein, Human (Biotinylated, HEK293, His-Avi)
CD162/PSGL-1 Protein, a cell surface receptor, plays a crucial role in leukocyte trafficking and adhesion. Dysregulation of CD162/PSGL-1 Protein has been associated with inflammatory diseases and impaired immune responses. Targeting CD162/PSGL-1 Protein may offer potential therapeutic interventions in these conditions by modulating leukocyte trafficking, enhancing immune responses, and managing inflammatory disorders. CD162/PSGL-1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

Species: Human; Source: HEK293

CD Antigens Biotinylated Proteins Macrophage CD Proteins PSGL-1/CD162

/
HY-P700816 CD162/PSGL-1 Protein, Mouse (HEK293, His)
The CD162/PSGL-1 protein is an SLe(x)-type proteoglycan that mediates rapid rolling of leukocytes through high-affinity interactions with E- and P-selectin, thereby promoting early inflammatory stages.CD162 forms homodimers linked by disulfide bonds and interacts with selectins through the lectin/EGF domain.CD162/PSGL-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived CD162/PSGL-1 protein, expressed by HEK293 , with C-His labeled tag.

Species: Mouse; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P701366 CDK6-CCND1 Heterodimer Protein, Human (sf9)
The CDK6ic complex is an important serine/threonine protein kinase that regulates cell cycle progression and differentiation, promoting the G1/S transition by phosphorylating substrates such as pRB/RB1 and NPM1. It interacts with D-type G1 cyclins during interphase to form active pRB/RB1 kinase, which controls cell cycle entry. CDK6-CCND1 Heterodimer Protein, Human (sf9) is a recombinant protein dimer complex containing human-derived CDK6-CCND1 Heterodimer protein, expressed by sf9 insect cells , with tag free.

Species: Human; Source: Sf9 insect cells

Enzymes & Regulators Kinases Transferases (EC 2) Serine/Threonine Kinase Proteins CMGC Cyclin-Dependent Kinases (CDKs) CDK Cyclin-Dependent Kinase 6 (CDK6)

/
HY-P702223 BCL2 Protein, Rat (Cell-Free, His)
The BCL2 protein is critical for inhibiting apoptosis in different cellular systems and regulates cell death by controlling mitochondrial membrane permeability. BCL2 operates in a feedback loop with caspases, inhibiting caspase activity by preventing cytochrome c release and binding to apoptosis-activating factor (APAF-1). BCL2 Protein, Rat (Cell-Free, His) is the recombinant rat-derived BCL2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag.

Species: Rat; Source: E. coli Cell-free

Enzymes & Regulators

/
HY-P705461 CD162/PSGL-1 Protein, Human (279a.a, HEK293, His)
CD162/PSGL-1 Protein, a cell surface receptor, plays a crucial role in leukocyte trafficking and adhesion. Dysregulation of CD162/PSGL-1 Protein has been associated with inflammatory diseases and impaired immune responses. Targeting CD162/PSGL-1 Protein may offer potential therapeutic interventions in these conditions by modulating leukocyte trafficking, enhancing immune responses, and managing inflammatory disorders. CD162/PSGL-1, Human (279a.a, HEK293, His) is the recombinant human-derived CD162/PSGL-1 protein, expressed by HEK293, with labeled tag.

Species: Human; Source: HEK293

CD Antigens Macrophage CD Proteins PSGL-1/CD162

/
HY-P83529 CD62P Antibody (YA3274)
CD62P Antibody (YA3274) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD62P.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P80094 Ctip1 Antibody (YA489)
Ctip1 Antibody (YA489) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Ctip1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81711 CD162 Antibody (YA1456)
CD162 Antibody (YA1456) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD162.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81536A Bcl-6 Antibody (YA1281)(PBS only)
Bcl-6 Antibody (YA1281) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-6.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P85808 Bcl-6 Antibody (YA5500)
Bcl-6 Antibody (YA5500) is a Mouse-derived and non-conjugated IgG3 monoclonal antibody, targeting to Bcl-6.

Host: Mouse; Reactivity: Human, Mouse,

Monoclonal Antibodies Primary Antibodies

/
HY-P81536 Bcl-6 Antibody (YA1281)
Bcl-6 Antibody (YA1281) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-6.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81737 CD62P Antibody (YA1482)
CD62P Antibody (YA1482) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD62P.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P84565 CD162 Antibody (YA4262)
CD162 Antibody (YA4262) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD162.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81443 Bcl-10 Antibody (YA1188)
Bcl-10 Antibody (YA1188) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-10.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81443A Bcl-10 Antibody (YA1188)(PBS only)
Bcl-10 Antibody (YA1188) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-10.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P84565A CD162 Antibody (YA4262)(PBS only)
CD162 Antibody (YA4262) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD162.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P84970 CD162 Antibody (YA4662)
CD162 Antibody (YA4662) is a non-conjugated antibody, targeting to CD162.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Nanobodies Primary Antibodies

/
HY-P87417A BCL9L Antibody (YA7105)(PBS only)
BCL9L Antibody (YA7105) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BCL9L.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P86688 Bcl-2 Antibody (YA6380)
Bcl-2 Antibody (YA6380) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86712 Bcl-2 Antibody (YA6404)
Bcl-2 Antibody (YA6404) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86712A Bcl-2 Antibody (YA6404)(PBS only)
Bcl-2 Antibody (YA6404) is a Mouse-derived and non-conjugated IgG monoclonal antibody, targeting to Bcl-2.

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/

Keywords

PSGL-1 | SELPLG | B-cell lymphoma | immune checkpoint | T-cell exhaustion | P-selectin